XNCR Xencor Inc.

36.27
+1.16  (+3%)
Previous Close 35.11
Open 35.1
Price To Book 3.38
Market Cap 2,053,616,830
Shares 56,620,260
Volume 191,067
Short Ratio
Av. Daily Volume 354,827
Stock charts supplied by TradingView

NewsSee all news

  1. Xencor to Present at the 2019 Cantor Global Healthcare Conference

    Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer, autoimmune disease, asthma and allergic diseases, today announced that

  2. Xencor Appoints Celia Eckert as Vice President, General Counsel and Corporate Secretary

    Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer, autoimmune diseases, asthma and allergic diseases, today announced the

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 2 top-line data released October 5, 2018. Primary endpoint not met.
XmAb5871
Systemic Lupus Erythematosus (SLE)
Phase 3 trial to be initiated - partner required.
XmAb5871
IgG4-Related Disease (IgG4-RD)
Phase 1 trial placed on partial clinical hold - February 20, 2019.
XmAb14045
Acute Myeloid Leukemia (AML)
Phase 1 initial data due 4Q 2019.
XmAb13676
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Phase 1 initial data due 1H 2020.
XmAb18087
Neuroendocrine tumors (NET) and gastrointestinal stromal tumors (GIST)
Phase 1 initiation of dosing announced May 6, 2019.
XmAb23104-01 (DUET-3)
Solid tumors
Phase 1 commencement of dosing announced June 3, 2019.
XmAb22841
Solid tumors
Phase 1 initial data due 1H 2020.
XmAb20717 (DUET-2)
Solid tumors

Latest News

  1. Xencor to Present at the 2019 Cantor Global Healthcare Conference

    Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer, autoimmune disease, asthma and allergic diseases, today announced that

  2. Xencor Appoints Celia Eckert as Vice President, General Counsel and Corporate Secretary

    Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer, autoimmune diseases, asthma and allergic diseases, today announced the